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IMMUNOLOGIC STUDIES IN THE LYMPHOBLASTOMAS
II. THE ABILITY TO DEVELOP AN ECZEMATOUS SENSITIZATION TO A
SIMPLE CHEMICAL AND THE ABILITY TO ACCEPT
PASSIVE TRANSFER ANTIBODY
A. ROSTENBERO, JR., M.D.,* H. C. McCRANEY, M.D.* AND SAMUEL M.
BLUEFARB, M.D.t
In a previous communication, we discussed certain cutaneous reactions in per-
sons having a lymphoblastomatous disease (1). It was shown that these patients
exhibited a marked reduction in the incidence of cutaneous reactivity to such
antigens as tuberculin, trichophytin and oidiomycin. It was assumed that they
had previously been exposed to the microorganisms from which these antigens
are derived. The depression of reactivity appeared to exist against both the
immediate and delayed types of allergic reaction but was much more marked
against the delayed type. There was no impairment in the ability to react to an
obligatory urticariogenic agent such as histamine or a histamine liberator.
MATERIAL AND TECHNIC
This study is concerned with the ability of patients having these diseases to
develop the eczematous variety of delayed allergic sensitization to a simple
chemical and also their ability to accept passive transfer antibody (Prausnitz-
KUstner reagin). We observed 37 patients having a variety of conditions in the
"lymphoma-leukemia" group. For comparison with this group, 14 ill, hospitalized
patients having diseases other than a "lymphoma-leukemia" were studied to
determine their ability to develop an eczematous sensitization to a simple
chemical. The exact diagnosis for each patient in both groups is given in Table I.
In our opinion, all the diagnoses were clearly established. Sternal marrow exam-
ination, lymph node biopsies and peripheral blood studies were done on all
"lymphoma-leukemia" patients.
To produce an eczematous sensitization, approximately 0.1 cc of a 10 percent
acetone solution of 2:4 dinitrochlorobenzene (2:4) was applied to a quarter-sized
area of normal skin on the volar surface of each arm and allowed to evaporate.
This site was observed for about 72 hours.
Approximately three weeks following the original application, 0.1 cc of a
1:1000 acetone solution of 2:4 was applied to another area of the skin and ob-
served for 72 hours.
To determine whether the patients would accept passive transference anti-
bodies, we used two human sera known to contain passive transference anti-
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TABLE I
Diagnoses
Lymphoma-Leukemia Group Number Control Group I Number
Reticulum cell sarcoma 2 Renal glycosuria 1
Lymphosarcoma 5 Carcinoma of thyroid 1
Acute leukemia 3 Ulcerative colitis 1
Chronic myeloid leukemia 5 Poliomyelitis—with paralysis
and/or respiratory embarass-
ment 5
Chronic lymphatic leukemia 10 Cardiomegaly and circulatory
Giant follicularlymphoblastoma. 1 failure 1
Hodgkin's disease 4 Nephritis and cardiovascular
Mycosis fungoides 1 disease 1
Multiple myeloma 6 Rheumatoid arthritis 1




Total cases 37 Total cases 14
bodies, one against guinea pig serum and the other against a ragweed protein
extract. Approximately 0.1 cc of each serum was injected as superficially as
practical. Twenty-four hours later, the prepared sites were injected with either
guinea pig serum diluted 1:10 or with ragweed extract. At the same time the two
antigens were injected into normal skin sites.
Sensitization to the simple chemical was attempted in 31 of the lymphoma-
leukemia patients and in all 14 of the control cases. Passive transfer studies were
done in 10 of the lymphoma-leukemia cases. No passive transference study was
done in any of the control cases.
RESULTS
All ten of the "lymphoma-leukemia" patients, on whom the passive trans-
ference was attempted, accepted the antibody normally.
Of the 31 patients having a "lymphoma-leukemia" disease, in whom it was
attempted to develop an eczematous sensitization, only one* developed a clear
sensitization. None of the subjects except this one exhibited a spontaneous
"flare-up" phenomenon. t
In the control group, 3 subjects clearly became sensitized and one questionably
* This patient was a 29 year old man with a chronic myeloid leukemia. He was appar-
ently in good physical condition when tested. Laboratory studies at this time were reported
to show 23,400 white blood cells with 64 per cent polymorphonuclears, 11 per cent lympho-
cytes, 2 per cent eosinophils, 5 per cent myelocytes, and 18 per cent juvenile forms. There
were 3,560,000 red blood cells, 10.5 g hemoglobin, and 211,000 blood platelets. He received
Myeleran, both before, during and following our investigative procedures.
t A spontaneous inflammation may develop at the site of the initial application. When it
develops, it does so usually between the 9th and the 12th day after the original application.
It almost invariably indicates that the subject has become generally sensitized.
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sensitized. The first 3 developed spontaneous flares, and one of them also showed
a reaction over the area of the upper arm which came into contact with the site
of the lower arm to which the 2:4 had been applied. The reason for labelling one
patient questionably sensitized was because at the time of reading the test
application he was in restraint, and, while there was erythema at the site of the
test application, we were not sure whether it had been caused by the restraint or
developed as a consequence of the application of the allergen. The arm to which
the 2:4 was not applied was also in restraint; but, inasmuch as it did not show
any erythema, the most probable explanation for the erythema was that the
patient had been sensitized.
DISCUSSION
It seems definite that there is no impairment of the ability of patients having
a disease of the lymphoma-leukemia group to accept passive transference anti-
body and to develop a normal urticarial reaction at the site of the fixation of
such antibody when exposed to the appropriate allergen.
This result was anticipated in view of our previous finding that these patients
react normally to obligatory urticariogenic agents. It was not known, however,
whether patients with these diseases would fix the passive transference antibody
normally.
Before discussing the question of an impairment in the ability of persons with
a "lymphoma-leukemia" disease to develop an eczematous sensitization to a
simple chemical, we should like to review some of the theory regarding the
pathogenesis of this type of sensitization. It is believed that the first step is the
formation of a conjugate of the simple chemical with proteins of the body,
probably epidermal. The next step is that this conjugated protein, which is
treated by the body as an alien one, causes an enzymatic adaptation in certain
cells, most probably the primitive reticulum cell and its various progeny, which
constitute the members of the lymphoreticular cell system. This enzymatic
adaptation is passed along to the descendents of these cells. When the host again
encounters the simple chemical, the same protein conjugate is produced, but
because the host possesses cells with enzyme systems specifically adapted to react
with the new protein, the eczematous reaction develops (2, 3).
In lymphomatous diseases, the process, regardless of its ultimate nature,
affects the very group of cells concerned in the development of sensitizations to
simple chemicals, as well as other varieties of immunologic reactions.
In view of these facts, and because we had previously shown that patients with
a lymphomatous disease have a markedly reduced ability to produce skin reac-
tions of the delayed tuberculin type (1) (a form of immunological response
believed to be closely related to the one under study), we believed it likely that
there would be impairment in the ability of such persons to develop an ecze-
matous sensitization to a simple chemical.
If the results of the present attempts to develop a sensitization in the lym-
phoma-leukemia group ar3 compared with similar previous studies, it is seen that
the yield of successful results, 1 out of 31, is extremely low. Sulzberger and
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Rostenberg (4), using a more or less identical technic and the same allergen,
sensitized 41 out of 82 subjects. Rostenberg and Kanof (5) sensitized 4 out of 29
subjects, but the strength of the 2:4, used as the sensitizing application, was
only one percent, which is one-tenth of that used in this study. It appears
definite that patients with a lymphoblastomatous disease have an impaired
ability to develop a sensitization to 2:4. The problem then arose as to whether
the lack of ability to develop a sensitization occurred because of a specific effect
of the diseases in question on cells concerned with immunologic phenomena, or
merely because these patients were generally quite ill, in which event the failure
to develop a sensitization might merely be an expression of the general non-
reactivity (negative anergy) sometimes present during illness.
The two previous studies referred to utilized persons who, as far as was known,
were in good general health. Therefore, in attempting to compare the present
results with the former, we are confronted with two points of difference, namely:
(1) a serious illness, with general debility, and (2) a specific disease affecting cells
of the lymphoreticular system. Although we could assert that there is a depres-
sion, we were not in a position to decide whether this effect was specific or non-
specific. It was for this purpose that we endeavored to develop an eczematous
sensitization in the 14 non-lymphomatous but chronically ill individuals. If there
was a difference in the incidence of sensitization in this group when compared
with the lymphoma-leukemia group, we would be able to assert that the differ-
ence presumably lay in the fact that the lymphoma group of diseases specifically
affects the cells which participate in this type of immunologic response.
With three or four of the 14 subjects comprising the seriously ill non-lymphoma
group becoming sensitized, it would seem clear that a chronic serious illness per se
does not prevent the development of sensitization to a simple chemical. A justi-
fiable conclusion appears to be that the impairment in ability of subjects with
lymphomatous diseases to develop a sensitization to a simple chemical stems
from the fact that the lymphomatous diseases specifically affect the cells of the
lymphoreticular apparatus.
Before accepting this conclusion unqualifiedly, it should be pointed out that
several aspects of this study are open to criticism, and consequently any conclu-
sions derived from it should be somewhat guarded. First, from a statistical
point of view, the difference between the number of patients who developed a
sensitization in the lymphoma-leukemia group (1 in 31) and in the group who
TABLE II
Distribution of patients according to race and sex
White Colored Totals
Male 22/7 7/5 29/12
Female 2/1 6/1 8/2
Totals 24/8 13/6 37/14
The numerator in each fraction is the appropriate number for the lymphoblastoma group
and the denominator, the corresponding number for the control group.
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* The ages of two patients were not obtained.
were ill, but who did not have a lymphomatous disease (3 or 4 in 14) is suggestive
but does not attain statistical significance. These results, therefore, might have
come about by chance alone. For example, through sheer accident the lymphoma-
leukemia group might have been composed of persons who, by virtue of their
genetic makeup, were particularly resistant to the development of an eczematous
sensitization, and, therefore, the low yield could have been because of this
hypothetical possibility rather than because of a specific effect of the lym-
phomatous process. Secondly, these two groups differ, apart from the nature of
their illness, in another respect, which may be important, namely, their respective
ages. As seen in Table III, the lymphoma-leukemia patients are considerably
older, the average age being 55.3 years, with about 43 % of this group being
60 years or older. In the ill, non-lymphomatous group, the average age was 37.8
years, and only 7 percent of this group was over 60 years. It is possible that aging
may affect this type of immunologic response (6, 7).
However, when comparing the present findings with our previous ones,
namely, that individuals with a lymphomatous disease have an impaired ability
to produce a delayed type of allergic reaction to antigens derived from micro-
organisms, to which they presumably had been exposed, it would appear more
than likely that the finding in the present study, which indicates that such
individuals have an impaired ability to develop an eczematous sensitization to a
simple chemical, is specifically ascribable to the effect of the disease process on
the cells of the lymphoreticular system. We believe the reason for this defect, as
suggested in our previous communication, is that the lymphomatous process
either prevents the cells of this system from acquiring the necessary enzymatic
adaptation, or that it is not maintained once acquired, or that the cell is not able
to pass the enzymatic adaptation on to its descendents.
SUMMARY AND CONCLUSIONS
1. It has been shown that patients having a lymphoma-leukemia disease
accept passive transfer antibody (Prausnitz-Kustner reagin) and react normally
to the specific allergen against this antibody.
2. It has also been shown that such individuals have an impaired ability to
develop an allergic eczematous sensitization to a simple chemical. It is believed
that this defect occurs because of a specific effect of the disease process on the
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cells of the lymphoreticular system, inasmuch as a control group consisting of
patients having a chronic, severe illness were apparently able to develop an
eczematous sensitization to the same simple chemical. However, it is stressed
that this latter conclusion cannot be accepted as fully established without further
investigation.
3. It is suggested that the lymphoblastomatous diseases, by virtue of affecting
the cells of the lymphoreticular system (the cells concerned with a variety of
immunologic processes), cause an impairment in all types of delayed allergic
reactivity.
BIBLIOGRAPHY
1. ROSTENBERG, A. JR. AND BLUEFARB, SAMUEL M.: Cutaneous Reactions in the Lympho-
blastomas. A.M.A. Arch. Dermat. & Syph. 69: 195 (February) 1954.
2. ROSTENBERG, A., JR.: Concepts of Allergic Sensitizations, Their Role in Producing
Occupational Dermatoses. Indust. Med. and Surg. 23: 1 (January) 1954.
3. ROSTENBERU, A., JR.: Studies on the Eczematous Sensitization. IV. Sensitization to
Metadinitrobenzene and Its Relation to 2:4 Dinitrochlorobenzene. Jn. Invest. Dermat.
24: 337 (March) 1955.
4. SULZBERGER, MARION B. AND ROSTENBERO, A., JR.: Acquired Specific Supersensitivity
(Allergy) to Simple Chemicals. Jn. Immunology 36: 17 (January) 1939.
5. ROSTENBERG, A., JR. AND KANOF, NAOMI M.: Studies in Eczematous Sensitizations. I.
Comparison Between the Sensitizing Capacities of Two Allergens and Between Two
Different Strengths of the Same Allergen and the Effect of Repeating the Sensitizing
Dose. Jn. Invest. Dermat. 4: 505 (December) 1941.
6. SHELMIRE, BEDFORD: Contact Dermatitis from Vegetation. Southern Med. Jn. 33: 337
(April) 1940.
7. KANOF, NAOMI M. AND RO5TENBERG, A., JR.: Observations on the Persistence of Sensi-
tivity of the Eczematous Type after Prolonged Periods of Removal from Contact with
the Allergen. Jn. Invest. Dermat. 4: 175 (April) 1941.
DISCUSSION
DR. RUDOLF L. BAER (New York, N. Y.): This is a very interesting addition
to the studies which Dr. Rostenberg and his co-workers have carried out in an
extremely important field. The general question as to what produces suscepti-
bility or lack of susceptibility to sensitization is one of the most basic problems
in allergic sensitization. Of course, we know something about local factors which
increase susceptibility and about certain chemical features which determine the
sensitizing capacity of a compound, but we know very little about systemic fac-
tors that influence susceptibility to sensitization and reactivity in the sensitized
organism.
Many years ago Dr. Sulzberger and I attempted to sensitize patients to picryl
chloride, i.e. not to dinitrochlorobenzene which is the substance used by Dr.
Rostenberg. We did these studies both in chronic disease patients without
cachectic disease (e.g. cases with various neurologic diseases) and in a series of
patients on a cancer ward, most of whom were cachectic. There was no question
about the fact that the incidence of sensitization to picryl chloride was much
lower in the cachectic cancer patients than in those with non-cachectic chronic
disease. This does not necessarily imply that the mechanism which blocked the
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sensitizability of these cachectic patients was the same as the one which was
operative in the lymphoblastoma patients studied by Dr. Rostenberg and his
collaborators.
DR. HERMANN PINKUS (Monroe, Michigan): It is of great interest that Dr.
Rostenberg and his group have now been able to show that the ability for epi-
dermal (eczematous) sensitization also is decreased in patients with lympho-
blastoma, not only tuberculin type allergy in which a specific damage to the
reticulo-endothelial system might be considered responsible. This new finding
seems to point to a more general damage of the immune system of cancer patients.
I hope it is not too far fetched if I mention some experiments that my coworkers
and I performed on mice affected with spontaneous mammary cancer. In this
case, no specific damage to the reticulo-endothelial system can be claimed, and
yet these mice showed decreased anaphylactic response to foreign protein. Also
it could be shown (Johnson, R. M., Albert, S., and Pinkus, H.: Serum proteins in
mice bearing induced and spontaneous mammary gland carcinomas, Cancer
Research 14: 830—836, December 1954.) that the amount of gamma globulin
began to decline in the blood serum even before the individual mice of the high
cancer C3H strain developed their spontaneous tumors. One might consider the
hypothesis that not only cancer in general is associated with a general decrease
of immune mechanisms, but that perhaps a breakdown of immune responses
precedes the development of cancer, be it carcinoma or lymphoblastoma.
DR. CARL T. NELSON (New York, N. Y.): I merely want to ask Dr. Rosten-
berg a question regarding the relative percentages of negroes and whites in the
lymphoblastoma series and the control group. Was there any apparent difference
in ease of sensitization in the two racial types?
J. WALTER WILSON (Los Angeles, Calif.): I am very glad you asked that
question because I think this paper has a direct bearing on something that
interests me very greatly and that is the relationship of immunological processes
in the various deep mycoses. I myself want to beg Dr. Rostenberg and Dr.
Bluefarb to pursue this type of study because there are only a few individuals
such as they in the world who are capable of carrying out investigations in this
very complicated field. Some of you have heard me publicly deny that I have
that ability. I have said that I started my medical education too early and that
it therefore is deficient, in not furnishing me with a background sufficient to
understand immunology at the present level. In this connection I like to para-
phrase the writings of another famous member of the Baer family, Arthur "Bugs"
Baer, who wrote, "After pitting my own college education against the world for a
number of years I have reluctantly come to the conclusion that my sheepskin
must have come from somewhere back near the tail."
I want people like Dr. Rostenberg to continue this type of study until we can
obtain the correct answers to vital problems in immensity.
DR. ADOLPH ROSTENBERG, JR. (Chicago, Ill.): I want to thank the various
discussers and I shall try to answer some of the questions, answering them more
or less in reverse order.
The point Dr. Nelson made about the distribution, of course, is a valid one.
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In the published report, we give all the details, which I should have mentioned;
and I will take this opportunity to do so. Our results, we think, are suggestive;
but in view of the fact that they fit our more or less preconceived ideas, we may
have a bias in interpreting them. We are dealing with relatively small numbers,
31 subjects, out of whom one became sensitized, versus a group of 14 out of whom
3 or 4 became sensitized. I would not categorically assert that in a larger series
one would not find a different result. Secondly, there is a difference between the
two groups, apart from the disease conditions, which is discussed in the written
paper; namely, age distribution. This may be of some significance.
In the lymphoblastoma group the average age was 55 years and 43 per cent of
the members were 60 years or older. In the non-lymphoblastoma group the
average age was 38 and only 7 per cent of its members were 60 years or over. It is
something to be considered in comparing differences between the groups.
As far as color and race, I don't think there was very much difference. They
were about equally divided. I don't think that in any case this plays any role.
In studies Dr. Kanof and I did some years ago, we could not see any real differ-
ence between the negro and the white races in ability to be sensitized to these
simple chemicals.
Dr. Pinkus's remarks are interesting and his studies are of importance. Just
how germane such studies are to the current one none of us know; as his deal with
immediate type of sensitivity in which there is apparently a good correlation
between allergic reaction and circulating antibody. One can also correlate
protein levels and antibody titers. Dr. Paul Cannon of the University of Chicago,
over the years has conducted many investigations which show that if an animal
is sufficiently depleted of protein it cannot manufacture antibodies. So I think
that if for any reason there is a significant protein depletion, there is apt to be an
impairment in ability to manufacture antibodies. It should be stressed though
that the antibodies of that type so far as we know have nothing whatsoever to do
with the kind of reactions about which we spoke. It might be that there is some
as yet unknown relationship, but this is pure speculation.
As to Dr. Orris' and Dr. Baer's remarks, I don't think I will have time to go
into them in any detail, nor ca I really answer many of their questions. I guess
by virtue of age and cerebral arteriosclerosis I had completely forgotten about
Dr. Baer's study.
